Wyeth DoJ probe

Executive Summary

Firm "expects to receive a subpoena in the near future" for Department of Justice inquiry "into allegations of collusive practices" with another drug company, Wyeth states in Feb. 11 SEC filing. Case has been referred to a grand jury, Wyeth says. Allegations refer to collusion "relating to commission rates for a sales broker for a small segment of the" firm's OTC business, filing notes, although Wyeth maintains "our practices regarding brokers have not violated the antitrust laws." Schering-Plough disclosed a similar investigation in November. DoJ initiated the inquiry following same-day move by the two firms to reduce fees to Compass Marketing (1"The Tan Sheet" Aug. 19, 2002, In Brief)...